Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Gel Gets Backing Of The EMA
Executive Summary
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
You may also be interested in...
EMA Suspends Leo’s Actinic Keratosis Drug Picato
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.
AlzeCure Confident Of Bagging Partner For Pain Drug
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.